Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | CuttingEdgeInfo Reports | Medical Affairs: Delivering Strategic Value (PH112)

Medical Affairs: Delivering Strategic Value (PH112)

Increase the effectiveness of your medical affairs efforts:

Medical affairs plays an instrumental role in providing medical and scientific perspectives for a company’s brands. While the function has long been considered vital, recent years have brought tremendous change. Pressure to remain compliant and increasing globalization have had a profound impact on companies’ medical affairs structures, budgets and strategies. This transition is exciting—it creates a motivator for dynamic growth opportunities that underscore medical affairs’ importance to pharma companies. At the same time, such growth spurs new challenges. Medical affairs teams often struggle to strike a balance— between serving both internal and external customers, as well as being faithful to clinical truths and contributing to commercial goals.

Cutting Edge Information’s report Medical Affairs: Delivering Strategic Value addresses the major trends of the medical affairs landscape. It benchmarks industry-leading medical affairs structures and explores best practices departments have implemented to remain compliant with regulatory guidelines. The report provides medical affairs departments with the tools to improve their functions by comparing their spending, staffing, global structures, and strategies to those of top pharmaceutical companies.

The report makes its case with metrics and techniques for managing medical affairs in these key areas:

* Structure, Communication and Globalization – Learn how and why pharmaceutical companies are restructuring their medical affairs departments. Explore department best practices in achieving optimal communication and coordination. Discover how medical affairs is growing globally.

* Budget, Staffing and Success Measurements – Examine top companies’ 2008 medical affairs budgets and staffing by activity. Discover what measures medical affairs departments use to gauge success.

* Strategy, Activities and Compliance – Explore medical affairs’ involvement in strategy-setting, as well as some of the major activities the function is responsible for. Understand how compliance has affected medical affairs today.

Companies Included in Report

Allergan

Amgen

Amylin

Bayer

Biogen Idec

CV Therapeutics

Dentsply Rinn

Dyax

EMD Serono

GlaxoSmithKline

Janssen Ortho-McNeil

Novartis

Sirion Therapeutics

Upsher-Smith

Published 2008

119 Pages

400+ Metrics

60+ Tables, Charts and Diagrams
Table of Contents
Price: $7,695.00 / €5,143.34

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions